2024
P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchP-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. P-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s251. DOI: 10.1016/s2152-2650(24)02279-1.Peer-Reviewed Original ResearchP-008 A Rare and Unexplored Entity of Colitis Post-BCMA Directed CAR T-Cell Therapy; Insights From a Multicenter Case Series
Bar N, Yee A, Dhakal B, Frigault M, Richard S, Cohen A, Susanibar-Adaniya S, Rossi A, Vogl D. P-008 A Rare and Unexplored Entity of Colitis Post-BCMA Directed CAR T-Cell Therapy; Insights From a Multicenter Case Series. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s44-s45. DOI: 10.1016/s2152-2650(24)01911-6.Peer-Reviewed Original ResearchP-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis
Mina R, Khan A, McClune B, Bar N, Caers J, Larsen J, Mendes J, Lee S, Benachour N, Chen D, Zhao M, Lonardi C, Slaughter A, Lengil T, Burnett H, Cichewicz A, Neupane B, Filho O, Dytfeld D, Sidana S. P-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s74. DOI: 10.1016/s2152-2650(24)01960-8.Peer-Reviewed Original ResearchP-030 Low Infection Rates in Patients (pts) With Relapsed/Refractory Myeloma (RRMM) Treated With Alnuctamab (ALNUC) in a Setting of Infection Reduction Strategies (IRS) and Less Frequent Dosing
Hofmeister C, Bar N, Martin T, Manteca M, Stefanoni P, Yee A, Ribas P, Santoro A, Hansson M, Rodríguez-Otero P, Thompson E, Kiesel B, Cao C, Chen J, Jeyaraju D, Gaudy A, Hsu K, Petrlik E, Godwin C, Costa L. P-030 Low Infection Rates in Patients (pts) With Relapsed/Refractory Myeloma (RRMM) Treated With Alnuctamab (ALNUC) in a Setting of Infection Reduction Strategies (IRS) and Less Frequent Dosing. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s57-s58. DOI: 10.1016/s2152-2650(24)01933-5.Peer-Reviewed Original ResearchComparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, Cost P, Schecter J, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Lopez-Muñoz N. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison. Current Medical Research And Opinion 2024, 40: 1597-1603. PMID: 39129504, DOI: 10.1080/03007995.2024.2391112.Peer-Reviewed Original ResearchRelapsed/refractory multiple myelomaEfficacy of ciltacabtagene autoleucelIde-celProgression-free survivalCilta-celIdecabtagene vicleucelCiltacabtagene autoleucelMultiple myelomaTreated with 2Risk of disease progressionDistribution of prognostic factorsIndirect comparisonsRefractory multiple myelomaTreatment of patientsCox proportional hazards modelsMatching-adjusted indirect comparisonWeighted Cox proportional hazards modelsLogistic regression analysisProportional hazards modelCARTITUDE-1Partial responseTriple-classPrognostic factorsPatient-level dataClinical benefitPrevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Peer-Reviewed Original ResearchAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucel
2023
Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience
Hamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.Peer-Reviewed Original ResearchT-cell lymphomaTotal body irradiationAggressive T-cell lymphomaReduced intensity conditioning regimenHematopoietic stem cell transplantationRefractory T-cell lymphomaNodal T-cell lymphomasIntensity conditioning regimenPotential curative optionStem cell transplantationConditioning regimenAdult patientsCurative optionRetrospective reviewBody irradiationCell transplantationSingle agentPatientsRegimenPentostatinAlloSCTTransplantationLymphomaComprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test resultsCAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediatorsMultimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders
Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.Peer-Reviewed Original ResearchBleeding tendencyBleeding disorderPlatelet markersPlatelet aggregometryMass cytometryPlatelet functionPlatelet disordersSingle-center prospective studyLow-risk groupAbnormal bleeding tendencyQualitative platelet disordersLarge patient cohortQuantitative platelet disordersCommon underlying causeGenetic variantsMultimodality evaluationTotal patientsRisk stratificationLaboratory suspicionPlatelet dysfunctionProspective studyPatient cohortUnivariate analysisPlatelet volumeRisk groupsAlnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Otero P, Bermúdez M, Martin T, Santoro A, Yee A, Creignou M, Rodriguez C, Cerchione C, De La Rubia J, Oriol A, Waibel H, Besemer B, Thompson E, Kiesel B, Chen J, Chung A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study. Blood 2023, 142: 2011. DOI: 10.1182/blood-2023-180013.Peer-Reviewed Original ResearchRelapsed/Refractory Multiple MyelomaTreatment-emergent adverse eventsT-cell engagersLines of therapyOverall response ratePhase 1 studyTarget dosesTarget doseMedian PFSData cutoffMedian timeSafety profileCD3 T-cell engagerUpper respiratory tract infectionAnti-CD38 therapyAntitumor activityGrade 1 neurotoxicityTreatment-related deathsCytokine release syndromeRefractory multiple myelomaRespiratory tract infectionsPhase 1 trialPopulation pharmacokinetic analysisHuman clinical studiesObserved trough concentrationsComparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Cost P, Schecter J, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Lopez-Muñoz N. Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2-4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison. Blood 2023, 142: 2141. DOI: 10.1182/blood-2023-182141.Peer-Reviewed Original ResearchIndividual patient-level dataMatching-adjusted indirect comparisonProgression-free survivalRefractory multiple myelomaCARTITUDE-1Overall response rateMultiple myelomaUnanchored matching-adjusted indirect comparisonIdecabtagene vicleucelHazard ratioCAR-TsKaplan-MeierComparative efficacyIndirect comparisonConfidence intervalsChimeric antigen receptor T-cell therapyB-cell maturation antigenCox proportional hazards modelGood partial responseTreatment of patientsT-cell therapyWeighted logistic regression analysisProportional hazards modelPatient-level dataLogistic regression analysisPULMONARY INVASIVE MUCORMYCOSIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
STEMPEL J, BAR N. PULMONARY INVASIVE MUCORMYCOSIS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION. CHEST Journal 2023, 164: a1049-a1050. DOI: 10.1016/j.chest.2023.07.768.Peer-Reviewed Original ResearchP-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
Costa L, Bar N, Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Boss I, Gaudy A, Hsu K, Godwin C, San-Miguel J, Wong S. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s52-s53. DOI: 10.1016/s2152-2650(23)01652-x.Peer-Reviewed Original ResearchP883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY
Wong S, Bar N, Victoria Mateos M, Ribas P, Hansson M, Paris L, Hofmeister C, Rodriguez-Otero P, Aranzazu Bermúdez M, Santoro A, Yee A, Creignou M, Encinas C, Cerchione C, de la Rubia J, Oriol A, Ferstl B, Besemer B, Chen J, Chung A, Boss I, Gaudy A, LI S, Hsu K, Godwin C, Burgess M, San-Miguel J, Jose Costa L. P883: ALNUCTAMAB (ALNUC; BMS‐986349; CC‐93269), A BCMA × CD3 T‐CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST‐IN‐HUMAN CLINICAL STUDY. HemaSphere 2023, 7: e1220745. PMCID: PMC10431068, DOI: 10.1097/01.hs9.0000970436.12207.45.Peer-Reviewed Original ResearchAiming for the cure in myeloma: Putting our best foot forward
Bar N, Firestone R, Usmani S. Aiming for the cure in myeloma: Putting our best foot forward. Blood Reviews 2023, 62: 101116. PMID: 37596172, DOI: 10.1016/j.blre.2023.101116.Peer-Reviewed Original ResearchConceptsMultiple myelomaMinimal residual disease negativityDeeper response ratesResponse-adapted strategyDuration of therapyPowerful prognostic factorSignificant inter-patient variabilityNovel clinical trialsInter-patient variabilityRegimen compositionFrontline therapyUpfront therapyPrognostic factorsMyeloma patientsMyeloma treatmentClinical trialsTreatment strategiesCurrent relevant literatureTreatment approachesResponse rateDisease riskTherapyMyelomaUse of transplantsCurrent standard
2022
Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel
Mirza A, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, VanOudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel. Blood 2022, 140: 10410-10412. DOI: 10.1182/blood-2022-168374.Peer-Reviewed Original ResearchAlnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
Wong S, Bar N, Paris L, Hofmeister C, Hansson M, Santoro A, Mateos M, Rodríguez-Otero P, Lund J, Encinas C, Yee A, Oriol A, Cerchione C, de la Rubia J, Ferstl B, Carlson K, Ribas P, Bermúdez A, Boss I, Gaudy A, Li S, Hsu K, Godwin C, Burgess M, San-Miguel J, Costa L. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study. Blood 2022, 140: 400-402. DOI: 10.1182/blood-2022-159009.Peer-Reviewed Original Research